ulmonary hypertension develops in most forms of hereditary and chronic hemolytic anemia, including sickle cell disease, 1 thalassemia, 2 hereditary spherocytosis, 3 and paroxysmal nocturnal hemoglobinuria, 4 suggesting that there is a clinical syndrome of hemolysis-associated pulmonary hypertension. This complication has been reported with increasing frequency in patients with sickle cell disease. 1, [5] [6] [7] [8] [9] [10] [11] Retrospective studies from tertiary care referral centers suggest a prevalence of pulmonary hypertension ranging from 20 to 40 percent. 9, 11, 12 Although these studies have demonstrated that patients with sickle cell disease have lower pulmonary pressures and higher cardiac output than patients with primary pulmonary hypertension, the two-year mortality rates approach 50 percent in both groups. 6, 10, 11, 13 The frequent reports of sudden death in adults with sickle cell disease in the absence of coronary artery disease and the high risk of sudden death in patients with sickle cell disease and pulmonary hypertension may be related. 5, 6, 14, 15 Such a relation would suggest that pulmonary hypertension may be a major cause of death in patients with sickle cell disease.
patients
To avoid tertiary care referral bias, we recruited 195 patients from the community through multimedia advertisements, community outreach, and regional clinics. All evaluated patients were screened by means of history taking and physical examination, laboratory studies, and transthoracic echocardiography. All patients provided written informed consent. The advertisements and protocol were approved by the institutional review boards of the National Heart, Lung, and Blood Institute and Howard University.
Patients with sickle cell hemoglobinopathy documented by high-pressure liquid chromatography were eligible for the study. Only outpatients in stable condition were included; patients who had had a vaso-occlusive crisis within the previous two weeks or an episode of acute chest syndrome within the previous four weeks were evaluated at a later time. Patients receiving transfusions were not excluded. In addition, 41 black control subjects, with age and sex distributions similar to those of the patients, were evaluated for race-based comparisons of laboratory and echocardiographic data. Transthoracic echocardiography was performed in all patients with the use of the Acuson Sequoia (Siemens) and Sonos 5500 (Philips) systems. Cardiac measurements were performed according to the guidelines of the American Society of Echocardiography. 16 Transmitral flow, Doppler determinations of the severity of valvular regurgitation, and left ventricular stroke volume were assessed and graded as previously described. [17] [18] [19] Peak velocities of the E wave and A wave, the ratio of the E wave to the A wave, and the deceleration time were measured in a standard manner. 20 Isovolumic relaxation time was measured as the time from aorticvalve closure to the start of mitral inflow.
Tricuspid regurgitation was assessed in the parasternal right ventricular inflow, parasternal short-axis, and apical four-chamber views, and a minimum of five sequential complexes were recorded. Continuous-wave Doppler sampling of the peak regurgitant jet velocity was used to estimate the right-ventricular-to-right-atrial systolic pressure gradient with the use of the modified Bernoulli equation (4¬[tricuspid regurgitant jet velocity] 2 ). 21 For the purpose of analysis, we prospectively defined pulmonary hypertension as a peak tricuspid regurgitant jet velocity of at least 2.5 m per second. Since most patients with clinically significant pulmonary hypertension have measurable tricuspid regurgitation, 21 we assumed that pulmonary-artery pressures were normal in patients with trace or no tricuspid regurgitation.
Pulmonary-artery systolic pressure was quantitated by adding the Bernoulli-derived pressure gradient to the estimated mean right atrial pressure. The mean right atrial pressure was calculated according to the degree of collapse of the inferior vena cava with inspiration: 5 mm Hg for a collapse of at least 50 percent and 15 mm Hg for a collapse of less than 50 percent. 22 right heart catheterization Right heart catheterizations were performed in 18 consenting patients with a tricuspid regurgitant jet velocity of at least 2.5 m per second.
statistical analysis
When tricuspid regurgitant jet velocity was analyzed as a continuous variable, undetectable values were assigned a value lower than any actually measured (1.3 m per second). 21 We used t-tests and Wilcoxon rank-sum tests to compare continuous varia-bles between patients with sickle cell disease and control subjects and the normal-approximation test to compare dichotomous variables, with no correction for continuity. For patients with sickle cell disease, associations between tricuspid regurgitant jet velocity and continuous variables were assessed by separate linear regression of each variable on tricuspid regurgitant jet velocity, defined as a categorical variable: 0 for values of less than 2.5 m per second, 1 for values of 2.5 to 2.9 m per second, and 2 for values of at least 3.0 m per second. Associations with dichotomous variables were assessed by means of the Armitage chi-square statistic for trend.
We used logistic-regression analysis of low values for tricuspid regurgitant jet velocity (less than 2.5 m per second) and high values (2.5 m per second or more) to obtain a set of variables that were independently associated with increasing jet velocity. Using both forward and backward selection methods in a stepwise procedure, we derived a model in which all variables had a calculated P value of less than 0.05 when they were added to the other variables in the model. We used proportional-hazards regression to assess variables that could be associated with an increased risk of death in patients with sickle cell disease. All regression analyses were performed with the use of log-transformed values (on a base 10 scale) for laboratory measurements in order to reduce the influence of extremely high values. Calculations were made with the use of Number Cruncher Statistical Systems software.
clinical characteristics
The base-line characteristics of all 195 patients who were evaluated and the 41 black control subjects are shown in Table 1 . The information for the patients is further categorized according to the values for tricuspid regurgitant jet velocity (less than 2.5 m per second, 2.5 to 2.9 m per second, and 3.0 m per second or more) in Table 2 . The genotype on the basis of hematologic and hemoglobin characteristics was hemoglobin SS in 132 patients (69 percent), hemoglobin SC in 35 (18 percent), and hemoglobin S-thalassemia ( b 0 or b + ) in 23 (12 percent). Data on genotype were missing for five patients.
prevalence and severity of pulmonary hypertension
Values for pulmonary-artery systolic pressure as estimated by Doppler echocardiography accurately predicted pulmonary-artery systolic pressures measured during right heart catheterization (25 catheterizations performed in 18 patients) (r=0.77, P<0.001) (Fig. 1C) . The patients with sickle cell disease had significantly higher mean values for tricuspid regurgitant jet velocity than did the controls (P=0.003) (Fig. 1A and 1B and Table 1 ). Thirtytwo percent of patients with sickle cell disease had elevated pulmonary-artery systolic pressures, as defined by a tricuspid regurgitant jet velocity of at least 2.5 m per second (an estimated pulmonary-artery systolic pressure of at least 30 mm Hg). Nine percent had pulmonary hypertension with the use of the more conservative cutoff value for tricuspid regurgitant jet velocity of at least 3.0 m per second (an estimated pulmonary-artery systolic pressure of at least 41 mm Hg) (Fig. 1A) . Of the 18 patients with a tricuspid regurgitant jet velocity of at least 2.5 m per second who underwent right heart catheterization, 17 had a mean pulmonary-artery pressure of more than 25 mm Hg (the definition of pulmonary hypertension used in the National Institutes of Health registry 23 ).
effect of pulmonary hypertension on ventricular size and function
Higher values for tricuspid regurgitant jet velocity were associated with increased cardiac-chamber sizes ( Table 2 ). There was a slight decrease in the ejection fraction at the highest levels of jet velocity (P=0.10). There was no association between jet velocity and stroke volume, and cardiac output increased slightly but not significantly with increasing jet velocity (P=0.24). There was qualitative evidence of left ventricular systolic dysfunction (an ejection fraction of 0.5 or less) in only 5 of the 195 patients.
Measurements of the left ventricular diastolic function are shown in Table 2 . Only the deceleration time was weakly associated with tricuspid regurgitant jet velocity (r=0.17, P=0.01), but the mean values remained in the normal range for all categories of tricuspid regurgitant jet velocity. Variables indicative of diastolic dysfunction did not contribute significantly to the logistic-regression model (Table 3) or affect the risk of death, suggesting that pulmonary hypertension is largely independent of diastolic dysfunction.
ed with high tricuspid regurgitant jet velocity; these factors, which accounted for approximately 35 percent of the variability in tricuspid regurgitant jet velocity (Table 3) , include a self-reported history of renal or cardiovascular problems; elevated systolic blood pressure, plasma lactate dehydrogenase levels, and alkaline phosphatase levels; and decreased plasma transferrin levels. In a model that included only men, priapism was an additional important variable (odds ratio for a jet velocity of at least 2.5 m per second, as compared with a value of less than 2.5 m per second, 5.0; 95 percent confidence interval, 1.5 to 17.0). Factors reflecting the presence of hemolysis, chronic anemia, and the need for fre- .001 by the Wilcoxon rank-sum test); the mean log value, on which the tabulated P value is based, was also higher in the controls. The new england journal of medicine quent blood transfusions, including low hemoglobin and hematocrit values, high lactate dehydrogenase and aspartate aminotransferase levels (but not high alanine aminotransferase levels, which are specific to liver dysfunction), high direct bilirubin levels, high iron and ferritin levels, low transferrin levels, and the receipt of a total of more than 10 transfusions, were all significant univariate predictors of a high tricuspid regurgitant jet velocity (Table 2) .
Increasing age, oxyhemoglobin desaturation as measured by pulse oximetry, and increasing levels of blood urea nitrogen, creatinine, and direct bilirubin were significant univariate -but not multivariate -predictors of high tricuspid regurgitant jet velocity. The plasma arginine:ornithine ratio, probably reflecting arginase activity, was low in patients with sickle cell disease, and this ratio decreased significantly as tricuspid regurgitant jet velocity increased. The fetal hemoglobin level, the pulmonary hypertension in sickle cell disease hemoglobin S-thalassemia phenotype ( b 0 or b + ), hydroxyurea therapy, the white-cell count, and the platelet count were not significantly associated with tricuspid regurgitant jet velocity, whereas the hemoglobin SC genotype was associated with a significantly reduced tricuspid regurgitant jet velocity (P=0.02 as calculated with the use of a t-test in which tricuspid regurgitant jet velocity was considered to be a continuous variable). Analysis of the patients who did not receive hydroxyurea or have hemoglobin C, as well as of all patients, showed no evidence of an association between the fetal hemoglobin level and tricuspid regurgitant jet velocity. The number of episodes of the acute chest syndrome and the number of visits to the emergency room per year were not associated with tricuspid regurgitant jet velocity (P=0.92 and P=0.68, respectively). The fact that there were significantly more patients with a self-reported history of cardiovascular problems who had pulmonary hypertension suggests that pulmonary hypertension and its complications, such as cor pulmonale, may be misdiagnosed as congestive heart failure.
right heart catheterization
Among the 18 patients who underwent right heart catheterization, the mean ( ± SE) values for pulmonary-artery systolic pressure (51.9 ± 4.1 mm Hg), diastolic pressure (26.1 ± 2.16 mm Hg), mean pulmonary-artery pressure (34.5 ± 2.7 mm Hg), pulmonary-artery wedge pressure (17.2 ± 1.2 mm Hg), cardiac output (10.2 ± 0.7 liters per minute as measured by thermodilution and 9.6 ± 0.4 liters per minute as calculated with the Fick equation), and pulmonary vascular resistance (148.5 ± 26.2 dyn·sec·cm ¡5 ) were similar to previously reported values in patients with sickle cell disease who had secondary pulmonary hypertension. Proportional-hazards regression analysis showed that patients with a tricuspid regurgitant jet velocity of at least 2.5 m per second had a significantly higher mortality rate than those with a jet velocity of less than 2.5 m per second (P<0.001) (Fig.  2) ; the rate ratio for death was 10.1 (95 percent confidence interval, 2.2 to 47.0). Analyses were also performed separately for age, cardiac output, stroke volume, the ratio for the E wave to the A wave, deceleration time, isovolumic relaxation time, hemoglobin level, fetal hemoglobin level, lactate dehydrogenase level, white-cell count, and creatinine level. Besides the tricuspid regurgitant jet velocity, the only significant univariate correlate of the risk of death was the creatinine level (P=0.007). After adjustment for the tricuspid regurgitant jet velocity, the creatinine level was not significantly related to the risk of death (P=0.08), whereas the jet velocity remained a significant independent correlate (P= 0.004).
Because we were concerned that pulmonary hypertension conferred a substantial risk of death, the study was not designed as a natural-history study. Patients and referring physicians were made aware of the results of echocardiography, and the patients who were identified as having severe pulmonary hypertension (on the basis of a tricuspid regurgitant jet velocity of at least 3.0 m per second) were offered treatments such as exchange transfusion, oxygen, and selective pulmonary vasodilator therapy according to a National Heart, Lung, and Blood Institute protocol. Eleven of the 17 patients with a tricuspid regurgitant jet velocity of at least 3.0 m per second began either an aggressive exchange-transfusion program or inhaled nitric oxide therapy after pulmonary hypertension was diagnosed, and 10 of these patients are still alive.
We found that the prevalence of pulmonary hypertension among patients with sickle cell disease was 32 percent, which is consistent with previously published retrospective studies. Despite having lower pulmonary-artery pressures and higher cardiac outputs than patients with primary pulmonary hypertension, patients with sickle cell disease and pulmonary hypertension had a significantly higher mortality rate than did patients with sickle cell disdiscussion ease who did not have pulmonary hypertension, a finding that is consistent with the results of previous retrospective studies. 6, 10, 11, 13 Our findings suggest that the noninvasive measurement of tricuspid regurgitant jet velocity by echocardiography can be used to identify patients at high risk for death and may thus be viewed as a prognostic tool analogous to transcranial carotid Doppler flow-velocity assessment, which is used to predict the risk of stroke in children with sickle cell disease. 24 The observation that markers of hemolysis are associated with pulmonary hypertension provides a link between sickle cell disease and other chronic hemolytic disorders and suggests that there is a distinct syndrome of hemolysis-associated pulmonary hypertension. Thalassemia, for example, is another chronic hemolytic disease that is associated with secondary pulmonary hypertension; the prevalence of pulmonary hypertension among patients with thalassemia ranges from 10 percent to 93 percent, depending on the patient population studied. 2, [25] [26] [27] [28] Patients with sickle cell disease and patients with thalassemia both have chronic hemolysis, which results in the release of hemoglobin into plasma. Plasma hemoglobin can scavenge nitric oxide as well as catalyze the formation of reactive oxygen and nitrogen species, processes that can lead to acute and chronic pulmonary vasoconstriction. 29 Hemolysis could also release erythrocyte arginase, as suggested by recent reports that arginase activity may be increased (a possibility that is consistent with our finding that arginine:ornithine ratios were significantly lower in patients than in control subjects) and that the bioavailability of arginine and nitric oxide is reduced in patients with sickle cell disease. [29] [30] [31] [32] [33] Hemoglobin-induced scavenging of nitric oxide results in transcriptional up-regulation of adhesion molecules such as vascular-cell adhesion molecule 1 and E-selectin and induces the expression of endothelin-1, a potent vasoconstrictor. [33] [34] [35] Indeed, endothelin-1 levels are elevated in the plasma of patients with primary pulmonary hypertension and patients with sickle cell disease. 36, 37 The statistical linkage among pulmonary hypertension, systolic systemic hypertension, and the hemolytic rate (associated with nitric oxide scavenging 29 ) is consistent with previous clinical observations that systemic hypertension is a risk factor for stroke and early death in patients with sickle cell disease. [38] [39] [40] Additional insults common to sickle cell disease and thalassemia that might lead to end-organ dysfunction and pulmonary hypertension include iron deposition, cirrhosis, anemia with a high cardiac-output state, and asplenism. Although cirrhosis can result in secondary pulmonary hypertension, cirrhosis and hepatic synthetic dysfunction were not common in our patients with pulmonary hypertension. It is unclear whether the significant increases in alkaline phosphatase and direct bilirubin in patients with pulmonary hypertension were due to more subtle liver dysfunction or to a secondary effect of pulmonary hypertension and increased passive liver congestion. The absence of an association between cardiac output and tricuspid regurgitant jet velocity in our study argues against a role for chronic anemia and a high cardiac-output state, leading to vascular remodeling and arteriopathy. If anemia itself were responsible, one would expect to find reports of pulmonary hypertension associated with iron-deficiency anemia, the most common cause of anemia in the world.
We were surprised that hydroxyurea therapy was not associated with lower tricuspid regurgitant jet velocity and that there was no significant association between the fetal hemoglobin level or the white-cell count and tricuspid regurgitant jet velocity; both are independent markers of disease severity and predic-* The analysis included 149 patients. Independent variables considered for the model were those thought to be possibly biologically related to tricuspid regurgitant jet velocity that were associated with a jet velocity of at least 2.5 m per second with a P value of 0.15 or less: age; deceleration time; systolic blood pressure; mean arterial pressure; oxygen saturation; receipt of a total of more than 10 blood transfusions; levels of creatinine, alkaline phosphatase, direct bilirubin, aspartate aminotransferase, lactate dehydrogenase, ferritin, iron, transferrin, and hemoglobin; presence of hemoglobin A; presence of hemoglobin C; and arginine:ornithine ratio. Log-transformed values were used for laboratory measurements to reduce the influence of extremely high values. † P values were calculated with the use of the likelihood ratio test. ‡ For numerical values, the odds ratio is given for the 25th and 75th percentiles (with all other independent variables held constant), calculated as e coefficient ¬(75 th percentile ¡ 25 th percentile) . For all variables simultaneously, the odds ratio is the product of the odds ratios for the individual variables (reciprocal taken for transferrin), or 1272. CI denotes confidence interval. tors of the outcome in sickle cell disease. 41 Although neither prospective nor randomized, our study suggests that hydroxyurea and other drugs that increase the expression of fetal hemoglobin may not prevent pulmonary hypertension. We speculate that this may be explained by the relatively limited induction of fetal hemoglobin associated with such therapy, the lack of full fetal-cell penetrance, and the presence of persistent hemolysis in most of our patients. Analysis of polymerization tendencies suggests that fetal hemoglobin levels of more than 25 percent in a pancellular distribution would be required to eliminate intracellular polymerization and hemolysis. 42, 43 This possibility is supported by the observation that hemoglobin C, which is present in all erythrocytes and reduces the rate of hemolysis, was associated with a reduced tricuspid regurgitant jet velocity.
In conclusion, pulmonary hypertension is common in adults with sickle cell disease and is associated with an ominous outcome. Our results support the use of Doppler echocardiographic screening in all adults with sickle cell disease to identify a highrisk group that may benefit from intervention. Therapeutic trials of oxygen, warfarin, transfusion, and pulmonary vasodilator and remodeling medications are urgently required to evaluate their potential to decrease the substantial morbidity and mortality associated with pulmonary hypertension in this population.
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